New drug trial aims to tame deadly lung condition ARDS
NCT ID NCT06564207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug fostamatinib can safely help adults hospitalized with acute respiratory distress syndrome (ARDS), a severe lung injury. About 40 participants will receive either the drug or a placebo, and researchers will track serious side effects for 30 days. The goal is to see if fostamatinib can control the disease and improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Stem cell infusion may help severely ill COVID-19 patients breathe
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?
- Could lung fluid proteins reveal a new way to track severe lung injury?
- Could a spirometer test guide breathing support in respiratory failure?
- Which ventilator setting saves more lungs? a Head-to-Head test